+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Human Liver Model Market Research and Forecast, 2019-2025

  • ID: 4766743
  • Report
  • April 2019
  • Region: Global
  • Orion Market Research Private Limited
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now


  • BioIVT, LLC
  • CN Bio Innovations Ltd.
  • Cyfuse Biomedical K.K.
  • Cyprotex PLC
  • EISCO Scientific LLC
  • Emulate, Inc.
  • MORE
Human Liver Model Market Size, Share & Trends Analysis Report, By Technology (Liver Organoids, 3D Bioprinting, 2D Models, Liver-On-A-Chip and Other), and Forecast, 2019-2025.

Human liver model is a structure that is intended for studying the toxicity associated with the drug which may result in liver failure and other liver diseases. This enables to develop a better understanding of liver disease and complex spatial relationships of the internal anatomy of the liver. Furthermore, various researches have reported for the development of human liver models to determine the sensitivity of drugs across a large amount of population. For instance, in February 2018, the Wake Forest Institute for Regenerative Medicine (WFIRM) created highly sophisticated mini-livers up to the current period. Such organoids can effectively support scientists to develop a better understanding of congenital liver disease. The model better mimics human liver functioning and fetal development. According to the center, these organoids are expected to advance their understanding of liver diseases, primarily congenital diseases that would enable for the development of improved treatments. This may support towards improving bioengineering of functional liver and bile ducts. The funding for the research was led by the state of North Carolina and the National Institutes of Health (NIH).

The research is remarkable in the area of liver transplantation and the study of biliary atresia which occurs in infants. Firstly, the scientists represented that such organoids generated hepatocytes which is capable to perform a large number of liver functions. The success for development of this model shows a major step towards the development of truly bioengineered liver tissue which is intended to transplantation into patients. This is exploring the significant opportunity for patients that require liver transplants. According to the American Liver Foundation, in 2016, in the US, the number of liver transplants performed were 7,841. Among these, 7,496 liver transplants were reported from deceased donors and 345 were from living donors. Additionally, as of February 2016, in the US, the reported number of patients waiting for liver transplants were 14,380. The development of such kind of human liver model is estimated to create new hope for patients that are waiting for liver transplant. It can overcome the problem associated with organ shortage. Other crucial factors that are contributing to the growth of the market include increasing prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) and rising focus of clinicians, pharmaceutical companies and academics towards drug-induced liver injury.

The global human liver model market is segmented on the basis of technology. Based on technology, the market is further classified into liver organoids, 3D bioprinting, 2D models, and liver-on-a-chip. These technologies utilize various cell source include primary hepatocytes, iPSC-derived, HepaRG, HepG2, and UpCyte. Primary hepatocytes represent approximately 60% of the total number of cells in the liver. Hence, it can perform a large number of liver functions and are usually accepted as the gold standard for building human liver models for drug testing and toxicity applications.

Geographically, the global human liver model market is segmented into four major regions, such as North America, Europe, Asia-Pacific, and RoW. North America was estimated to hold the largest share in 2017. This is resulting due to funding for the development of human liver models and significant healthcare spending in the region. However, Asia-Pacific is estimated to witness optimistic growth during the forecast period due to the increasing prevalence of NAFLD and improving healthcare infrastructure.

The major companies working in the market comprise InSphero AG, BioIVT, LLC, and Organovo Holdings, Inc. These companies are adopting several strategies, such as merger and acquisitions, product launches and collaboration and partnership to expand market share. For instance, in March 2018, BioIVT, LLC acquired Ascendance Biotechnology, which was established in 2015 from the merger of BioTime Inc.’s ESI BIO products division and Hepregen Corp. to develop a multinational cell-based assay firm. With this acquisition, BioIVT is including Hepregen’s HepatoMune, HepatoStem, and HepatoPac stem cell and liver cell product lines to its drug toxicology and drug safety testing portfolios. BioIVT has anticipated that widened use of highly functional Hepregen’s, in-vitro liver models would develop a significant understanding of the toxicity that results from long-term exposure to chemical compounds. This, in, turn, would support drug pre-clinical testing and other screening processes.

Research Methodology

The market study of the global human liver model market is incorporated by extensive primary and secondary research . Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Authentic public databases
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.
The report is intended for research institutes, government and private companies for overall market analysis and competitive analysis. The report provides in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

The Report Covers:
  • Comprehensive research methodology of the global human liver model market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global human liver model market.
  • Insights about market determinants which are stimulating the global human liver model market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown
2 of 3


  • BioIVT, LLC
  • CN Bio Innovations Ltd.
  • Cyfuse Biomedical K.K.
  • Cyprotex PLC
  • EISCO Scientific LLC
  • Emulate, Inc.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion

3. Competitive Landscape
3.1. Competitive Dashboard
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. Global Human Liver Model Market by Technology
5.1.1. Liver Organoids
5.1.2. 3D Bioprinting
5.1.3. 2D Models
5.1.4. Liver-On-A-Chip
5.1.5. Other

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. Japan
6.3.3. India
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles
7.1. BioIVT, LLC
7.2. CN Bio Innovations Ltd.
7.3. Cyfuse Biomedical K.K.
7.4. Cyprotex PLC
7.5. EISCO Scientific LLC
7.6. Emulate, Inc.
7.7. InSphero AG
7.9. Organovo Holdings, Inc.
7.10. Poietis SAS
7.11. Strand Life Sciences Pvt. Ltd.
Note: Product cover images may vary from those shown
3 of 3
  • BioIVT, LLC
  • CN Bio Innovations Ltd.
  • Cyfuse Biomedical K.K.
  • Cyprotex PLC
  • EISCO Scientific LLC
  • Emulate, Inc.
  • InSphero AG
  • Organovo Holdings, Inc.
  • Poietis SAS
  • Strand Life Sciences Pvt. Ltd.
Note: Product cover images may vary from those shown